Topic: idiopathic pulmonary fibrosis
With Boehringer Ingelheim aiming wide in its clinical program for pulmonary fibrosis med Ofev, a new FDA nod should validate its quest.
Boehringer Ingelheim is riding high on its idiopathic pulmonary fibrosis med Ofev. New data in a slew of rare diseases could keep the momentum up.
Former New York Yankees baseball star Bernie Williams is back in Boehringer Ingelheim’s newest idiopathic pulmonary fibrosis work.
In Boehringer Ingelheim’s first branded TV ad for its idiopathic pulmonary fibrosis treatment Ofev, the spotlight is not on the patient, but on a loved one.
A year after tapping a former Yankees star for its "Breathless" push, Boehringer Ingelheim had another surprise for baseball fans this opening day.
Boehringer Ingelheim wants to move its drug nintedanib into the scleroderma market. Meanwhile, it’s working to expand awareness of the disease, too.
This week, both IPF drugmakers upped the ante with positive new data for their contenders at the American Thoracic Society's annual meeting.